ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Sep 2, 2025 · CIK: 1715925
| Field | Detail |
|---|---|
| Company | Immunoprecise Antibodies LTD. (HYFT) |
| Form Type | 6-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
IPA files 6-K with press release update for Sept 2025.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on September 2, 2025, reporting on activities for the month of September 2025. The filing includes a press release dated September 2, 2025, as Exhibit 99.1. The company is incorporated in A1 and has its principal executive offices in Austin, Texas.
Why It Matters
This filing provides an update on the company's activities and includes a press release, which may contain material information for investors regarding its business operations or strategic developments.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to submit a press release, indicating no immediate significant financial or operational changes are being disclosed.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- September 2, 2025 (date) — Date of the press release and filing
- Jennifer Bath (person) — Signatory for the company
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information that ImmunoPrecise Antibodies Ltd. has made or is required to make public in Canada, distribute or make public outside of Canada, or is otherwise required to file with the SEC, including a press release dated September 2, 2025.
What is included as an exhibit in this filing?
Exhibit 99.1, a Press Release dated September 2, 2025, is included in this filing.
Where are ImmunoPrecise Antibodies Ltd.'s principal executive offices located?
ImmunoPrecise Antibodies Ltd.'s principal executive offices are located at Industrious, 823 Congress Ave Suite 300, Austin, Texas 78701.
Does ImmunoPrecise Antibodies Ltd. file annual reports under Form 20-F or Form 40-F?
ImmunoPrecise Antibodies Ltd. indicates that it files annual reports under Form 20-F.
Who signed this report on behalf of ImmunoPrecise Antibodies Ltd.?
The report was signed by /s/ Jennifer Bath on behalf of ImmunoPrecise Antibodies Ltd.
Filing Stats: 144 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-09-02 08:58:58
Filing Documents
- press_release_september_.htm (6-K) — 25KB
- ipa-ex99_1.htm (EX-99.1) — 12KB
- 0000950170-25-112350.txt ( ) — 38KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: September 2, 2025 By: /s/ Jennifer Bath Name: Jennifer Bath Title: President and Chief Executive Officer